Large scale chromatographic purification of alpha 1-antitrypsin from human plasma supernatant II + III.

T. Burnouf; J. Constans; A. Clerc; J. Descamps; L. Martinache; M. Goudemand

Large scale chromatographic purification of alpha 1-antitrypsin from human plasma supernatant II + III.

T. Burnouf, J. Constans, A. Clerc, J. Descamps, L. Martinache, M. Goudemand

Research output: Contribution to journal › Article › peer-review

Abstract

We describe a large-scale chromatographic method to purify alpha 1-antitrypsin (AAT) from human plasma supernatant II + III. Supernatant II + III was injected onto DEAE sepharose CL 6B to get an albumin-rich fraction as well as a fraction that contained about 45% AAT. This intermediate purity AAT fraction was further purified by size-exclusion chromatography on Sephacryl S-200. The product was heated in solution at 60 degrees C for 10 hours in the presence of a stabilizer to lower the risk of transmission of viral diseases. Purity of the AAT concentrate is over 85%; clinical testing of its safety and efficacy in the treatment of PiZ patients is underway.

Original language	English
Pages (from-to)	31-38
Number of pages	8
Journal	Developments in Biological Standardization
Volume	67
Publication status	Published - 1987
Externally published	Yes

ASJC Scopus subject areas

General Immunology and Microbiology
Drug Discovery
Public Health, Environmental and Occupational Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{edb5dc13c1124646957f1636bc51f8b5,

title = "Large scale chromatographic purification of alpha 1-antitrypsin from human plasma supernatant II + III.",

abstract = "We describe a large-scale chromatographic method to purify alpha 1-antitrypsin (AAT) from human plasma supernatant II + III. Supernatant II + III was injected onto DEAE sepharose CL 6B to get an albumin-rich fraction as well as a fraction that contained about 45% AAT. This intermediate purity AAT fraction was further purified by size-exclusion chromatography on Sephacryl S-200. The product was heated in solution at 60 degrees C for 10 hours in the presence of a stabilizer to lower the risk of transmission of viral diseases. Purity of the AAT concentrate is over 85%; clinical testing of its safety and efficacy in the treatment of PiZ patients is underway.",

author = "T. Burnouf and J. Constans and A. Clerc and J. Descamps and L. Martinache and M. Goudemand",

year = "1987",

language = "English",

volume = "67",

pages = "31--38",

journal = "Developments in Biological Standardization",

issn = "0301-5149",

publisher = "S. Karger AG",

}

TY - JOUR

T1 - Large scale chromatographic purification of alpha 1-antitrypsin from human plasma supernatant II + III.

AU - Burnouf, T.

AU - Constans, J.

AU - Clerc, A.

AU - Descamps, J.

AU - Martinache, L.

AU - Goudemand, M.

PY - 1987

Y1 - 1987

N2 - We describe a large-scale chromatographic method to purify alpha 1-antitrypsin (AAT) from human plasma supernatant II + III. Supernatant II + III was injected onto DEAE sepharose CL 6B to get an albumin-rich fraction as well as a fraction that contained about 45% AAT. This intermediate purity AAT fraction was further purified by size-exclusion chromatography on Sephacryl S-200. The product was heated in solution at 60 degrees C for 10 hours in the presence of a stabilizer to lower the risk of transmission of viral diseases. Purity of the AAT concentrate is over 85%; clinical testing of its safety and efficacy in the treatment of PiZ patients is underway.

AB - We describe a large-scale chromatographic method to purify alpha 1-antitrypsin (AAT) from human plasma supernatant II + III. Supernatant II + III was injected onto DEAE sepharose CL 6B to get an albumin-rich fraction as well as a fraction that contained about 45% AAT. This intermediate purity AAT fraction was further purified by size-exclusion chromatography on Sephacryl S-200. The product was heated in solution at 60 degrees C for 10 hours in the presence of a stabilizer to lower the risk of transmission of viral diseases. Purity of the AAT concentrate is over 85%; clinical testing of its safety and efficacy in the treatment of PiZ patients is underway.

UR - http://www.scopus.com/inward/record.url?scp=0023067448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023067448&partnerID=8YFLogxK

M3 - Article

C2 - 3497064

AN - SCOPUS:0023067448

SN - 0301-5149

VL - 67

SP - 31

EP - 38

JO - Developments in Biological Standardization

JF - Developments in Biological Standardization

ER -

Large scale chromatographic purification of alpha 1-antitrypsin from human plasma supernatant II + III.

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this